Posez n’importe quelle question sur les cours, conférences, exercices, recherches, actualités, etc. de l’EPFL ou essayez les exemples de questions ci-dessous.
AVERTISSEMENT : Le chatbot Graph n'est pas programmé pour fournir des réponses explicites ou catégoriques à vos questions. Il transforme plutôt vos questions en demandes API qui sont distribuées aux différents services informatiques officiellement administrés par l'EPFL. Son but est uniquement de collecter et de recommander des références pertinentes à des contenus que vous pouvez explorer pour vous aider à répondre à vos questions.
G protein-coupled receptors (GPCRs) represent the largest class of therapeutic targets, and peptides have become an increasingly important and versatile ligand type for studying receptor biology and developing new drugs. Although many core pharmacological concepts apply to all ligand classes, recent advances in peptide-focused approaches, from innovative discovery strategies and combinatorial library synthesis to computational design and structural integration, have substantially broadened the GPCR drug discovery toolbox. In this Primer, we outline experimental and computational workflows tailored to peptide–GPCR interactions, including in silico peptide mining, deorphanization strategies, library-based screening platforms, modern pathway-resolved biosensor assays, and approaches for peptide stabilization and optimization strategies to address their pharmacokinetic limitations. We summarize recent progress in structural modelling, diffusion-based de novo design, molecular dynamics simulations, and free energy calculations, as well as artificial intelligence-guided or machine learning-guided screening frameworks that connect peptide sequence space with receptor binding and functional signalling outcomes. We also discuss key challenges in the field, including reproducibility issues, ambiguity in sequence annotation and post-translational modifications, peptide instability, assay artefacts and current limitations of computational mining approaches, and we propose practical strategies to address them. Finally, we outline future perspectives, emphasizing integrated workflows that combine experimental pharmacology, structural biology and computational modelling to accelerate the discovery of next-generation peptide probes and therapeutic ligands targeting GPCRs.